Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jul;31(5):1013-1023.
doi: 10.1080/09273948.2022.2081584. Epub 2022 Jun 30.

The Efficacy of Golimumab Against Non-Infectious Uveitis: A PRISMA-Compliant Systematic Review and Meta-Analysis

Katsuya Okada  1   2 , Yi Zhou  3 , Noriyasu Hashida  3 , Tatsuya Takagi  1 , Yu-Shi Tian  1
Affiliations
Meta-Analysis

The Efficacy of Golimumab Against Non-Infectious Uveitis: A PRISMA-Compliant Systematic Review and Meta-Analysis

Katsuya Okada et al. Ocul Immunol Inflamm. 2023 Jul.

Abstract

Purpose: In this PRISMA-compliant systematic review and meta-analysis, we aimed to assess the efficacy of golimumab (GOL) against non-infectious uveitis (NIU).

Methods: We included eight articles in the meta-analysis. The primary outcome was inflammation remission. Secondary outcomes were changes in the number of uveitis relapses/attacks, mean best-corrected visual acuity, central macular thickness, and systemic corticosteroid-sparing effects.

Results: In total, eight case series with 172 patients (43.6% female) were collected. Patients had 75% (95% CI: 56-87%) of remission; 42% (0.12-0.80) of patients showed improved visual acuity. The average central macular thickness decline was 38 μm (-56.51-18.54). The pooled results showed a significant decrease in the use of systemic corticosteroids.

Conclusion: This study was limited by the use of non-RCT designs, limited sample sizes for outcomes, and heterogenetic underlying diseases. Our results suggest that GOL is effective against NIU. However, further evidence and analyses are required. (Funding: None; PROSPERO registration: CRD42021266214.).

Keywords: A systematic review; TNF-α inhibitor; golimumab; meta-analysis; uveitis.

PubMed Disclaimer

LinkOut - more resources